UC Urges Fed. Circ. To Nix 'Unjust' Gene Editing Patent Ruling

By Ryan Davis (July 26, 2017, 6:39 PM EDT) -- The University of California urged the Federal Circuit Tuesday to overturn a Patent Trial and Appeal Board decision favoring a research institute associated with Harvard and MIT in a hotly contested patent dispute over the breakthrough gene-editing technology CRISPR, calling the ruling "profoundly erroneous" and "unjust."

UC filed its opening brief in an appeal of a February PTAB decision that ended a proceeding known as an interference to determine which of two competing research teams was the first to invent CRISPR. The board held that the inventions claimed by the teams were distinct and that UC's claims did not render obvious...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!